Radiopharmaceuticals in Nuclear Medicine Market, By Product Type (Diagnostic Nuclear Medicine (SPECT Radiopharmaceuticals and PET Radiopharmaceuticals) and Therapeutic Nuclear Medicine), By Application (Oncology, Cardiology, Neurology, Endocrinology, and

Radiopharmaceuticals in Nuclear Medicine Market, By Product Type (Diagnostic Nuclear Medicine (SPECT Radiopharmaceuticals and PET Radiopharmaceuticals) and Therapeutic Nuclear Medicine), By Application (Oncology, Cardiology, Neurology, Endocrinology, and Others), By End User (Hospitals, Specialty Clinics, and Diagnostic Centers), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Therapeutic applications of radiopharmaceuticals include treatment of specific cancers under specific conditions. For instance, Yttrium-90 Ibritumomab Tiuxetan (Zevalin, Spectrum Pharmaceuticals) is indicated for the treatment of relapsed or refractory, low-grade or follicular B-cell non-Hodgkin’s lymphoma (NHL) and treatment of previously untreated follicular NHL in patients who achieve a partial or complete response to first-line chemotherapy. Also, Radium-223 dichloride (Xofigo, Bayer HealthCare Pharmaceuticals Inc.) is indicated for the treatment of patients with castration-resistant prostate cancer, and symptomatic bone metastases and no known visceral metastatic disease. Hence, increasing prevalence of cancer is expected to drive the market growth over the forecast period. According to the Cancer Research UK, in 2014, around 357,000 new cancer cases were diagnosed in the U.K., accounting for 980 cases diagnosed per day. Breast, prostate, lung, and bowel cancers together accounted for over 53% of the total cancers in the U.K.
Market Dynamics
Market players are focusing on various inorganic growth strategies such as collaboration and partnership agreements in order to expand their market presence, which is expected to boost growth of the global radiopharmaceuticals in nuclear medicine market over the forecast period. For instance, in October 2018, Cardinal Health Inc. and Telix Pharmaceuticals Inc., a subsidiary of Telix Pharmaceuticals Limited, entered into a distribution agreement. As per the agreement, Cardinal Health will both distribute the 69Ga-PSMA Kit and prepare unit doses of 68Ga-PSMA delivered as an investigational product for use in qualified investigator-sponsored clinical trials, including Telix-sponsored clinical trials.
Similarly, in January 2021, Progenics Pharmaceuticals, Inc. and Curium Pharma entered into an agreement to develop and commercialize PyL in Europe. PyL is Progenics’ PSMA-targeted small molecule PET/CT imaging agent, designed to visualize prostate cancer, which is in Phase 3 development.
Key features of the study:
This report provides in-depth analysis of the global radiopharmaceuticals in nuclear medicine market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022 - 2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global radiopharmaceuticals in nuclear medicine market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Progenics Pharmaceuticals, Inc., NorthStar Medical Radioisotopes LLC, Curium Pharma, Life Molecular Imaging, Lantheus Holdings, Inc., Cardinal Health, Inc., General Electric Company, Bracco S.p.A., Bayer AG, Advanced Accelerator Applications, S.A., Eli Lilly and Company, Nihon Medi-Physics. Co. Ltd., FUJIFILM Toyama Chemical Co., Ltd., Jubilant Life Sciences Ltd., Samyoung Unitech, and DuChemBio, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global radiopharmaceuticals in nuclear medicine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global radiopharmaceuticals in nuclear medicine market.
Detailed Segmentation:
Global Radiopharmaceuticals in Nuclear Medicine Market, By Product Type:
Diagnostic Nuclear Medicine
SPECT Radiopharmaceuticals
PET Radiopharmaceuticals
Therapeutic Nuclear Medicine
Global Radiopharmaceuticals in Nuclear Medicine Market, By Application:
Oncology
Cardiology
Neurology
Endocrinology
Others
Global Radiopharmaceuticals in Nuclear Medicine Market, By End User:
Hospitals
Specialty Clinics
Diagnostic Centers
Global Radiopharmaceuticals in Nuclear Medicine Market, By Region:
North America
By Product Type:
Diagnostic Nuclear Medicine
SPECT Radiopharmaceuticals
PET Radiopharmaceuticals
Therapeutic Nuclear Medicine
By Application
Oncology
Cardiology
Neurology
Endocrinology
Others
By End User:
Hospitals
Specialty Clinics
Diagnostic Centers
By Country:
U.S.
Canada
Latin America
By Product Type:
Diagnostic Nuclear Medicine
SPECT Radiopharmaceuticals
PET Radiopharmaceuticals
Therapeutic Nuclear Medicine
By Application
Oncology
Cardiology
Neurology
Endocrinology
Others
By End User:
Hospitals
Specialty Clinics
Diagnostic Centers
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Product Type:
Diagnostic Nuclear Medicine
SPECT Radiopharmaceuticals
PET Radiopharmaceuticals
Therapeutic Nuclear Medicine
By Application
Oncology
Cardiology
Neurology
Endocrinology
Others
By End User:
Hospitals
Specialty Clinics
Diagnostic Centers
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Product Type:
Diagnostic Nuclear Medicine
SPECT Radiopharmaceuticals
PET Radiopharmaceuticals
Therapeutic Nuclear Medicine
By Application
Oncology
Cardiology
Neurology
Endocrinology
Others
By End User:
Hospitals
Specialty Clinics
Diagnostic Centers
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Product Type:
Diagnostic Nuclear Medicine
SPECT Radiopharmaceuticals
PET Radiopharmaceuticals
Therapeutic Nuclear Medicine
By Application
Oncology
Cardiology
Neurology
Endocrinology
Others
By End User:
Hospitals
Specialty Clinics
Diagnostic Centers
By Country:
GCC
Israel
Rest of Middle East
Africa
By Product Type:
Diagnostic Nuclear Medicine
SPECT Radiopharmaceuticals
PET Radiopharmaceuticals
Therapeutic Nuclear Medicine
By Application
Oncology
Cardiology
Neurology
Endocrinology
Others
By End User:
Hospitals
Specialty Clinics
Diagnostic Centers
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Progenics Pharmaceuticals, Inc.*
Company Overview
Material Portfolio
Financial Performance
Key Highlights
Market Strategies
NorthStar Medical Radioisotopes LLC
Curium Pharma
Life Molecular Imaging
Lantheus Holdings, Inc.
Cardinal Health, Inc.
General Electric Company
Bracco S.p.A.
Bayer AG
Advanced Accelerator Applications, S.A.
Eli Lilly and Company
Nihon Medi-Physics. Co. Ltd.
FUJIFILM Toyama Chemical Co., Ltd.
Jubilant Life Sciences Ltd.
Samyoung Unitech
DuChemBio, Inc.
“*” marked represents similar segmentation in other categories in the respective section.